|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| Cash flow from operating activities | |||||
| Net income loss | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities | |||||
| Stock-based compensation | |||||
| Amortization of right of use assets | |||||
| Depreciation | |||||
| Change in fair value of warrant liability | |||||
| (Increase) decrease in operating assets | |||||
| Prepaid drug product | |||||
| Other current assets | |||||
| Increase (decrease) in operating liabilities | |||||
| Accounts payable and accrued expenses | |||||
| Lease liabilities | |||||
| Net cash used in operating activities | |||||
| Purchases of furniture, fixtures & equipment | |||||
| Cash flow from financing activities | |||||
| Net proceeds from exercise of warrants | |||||
| Net cash provided by financing activities | |||||
| Net decrease in cash | |||||
| Cash, beginning of period | |||||
| Cash, end of period | |||||
| Supplemental disclosure of non-cash activities | |||||
| Supplemental disclosure of non-cash activities | |||||
| Right of use asset recognized in exchange for lease obligation |
Loading...